KZIA Stock: Kazia Therapeutics Limited Stock Price, Analysis & Insights
Get live kzia stock price $7.85, comprehensive Kazia Therapeutics Limited stock analysis, charts, news, and expert forecast. Real-time kzia stock data and investment insights.
Loading chart...
Company Overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Company Information
- CEO
- John Edwin Friend II,
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
Contact Information
- Address
- Three International Towers
- Country
- AU
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.72)
Business Model & Strategy
Kazia Therapeutics Limited operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO John Edwin Friend II,, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Kazia Therapeutics Limited competes in the Biotechnology within the broader Healthcare. With 12.7 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Kazia Therapeutics Limited provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Kazia Therapeutics Limited should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Kazia Therapeutics Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Kazia Therapeutics Limited
- ⚠Investors should consider how Kazia Therapeutics Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
12.72M
P/E Ratio
-0.64
Beta
1.72
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 12.72M market capitalization
- Trading Volume: 22.54M shares traded today
- Price Range: 52-week range of $2.86 - $30.05
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Kazia Therapeutics Limited
Kazia Therapeutics Limited (KZIA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 12.72M, the company represents a significant player in its market. The stock is currently trading at $7.85 with a positivedaily change of 36.34%.
The company's 9 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.64, beta of 1.72, and 52-week price range from $2.86 to $30.05when evaluating investment opportunities.
Why Invest in Kazia Therapeutics Limited?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under John Edwin Friend II,
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.